Hey there, web surfer!

To search and monitor rising trends,
create an account here. It's free.

Join Treendly

live demand report in US

Ally Stock Trading Review

Finance     

  

Track this trend
(Monitor this trend over time)
 12 Months
 5 Years

We had problems fetching data for this keyword/topic.
Please update results by clicking the button below.

Refresh data

We had problems fetching data for this keyword/topic.
Please update results by clicking the button below.

Refresh data

Latest forum discussions

We tracked 2 total in the last 3 months

How Biogen Fumbled Aduhelm, Its Once-Promising Alzheimer's Drug; Early results were so impressive the company raced toward regulatory approval, but its decision to stop trials produced a therapy without proven efficacy
... the price. The company's stock is trading at about half its 2021 ... the agency conducted a thorough review of Aduhelm's data and ... saw Dr. Dunn as an ally who had been supportive of ... who spearheaded the FDA statistical review—began meeting regularly after the ... FDA approved Aduhelm. Biogen's stock closed at $395.85 that ... Institute for Clinical and Economic Review, a nonprofit research and advisory ...
jerrykrause
Published on 2022-01-04 in the BIIB forum
This discussion is in English.
How Biogen Fumbled Aduhelm, Its Once-Promising Alzheimer's Drug
... the price. The company's stock is trading at about half its 2021 ... the agency conducted a thorough review of Aduhelm's data and ... saw Dr. Dunn as an ally who had been supportive of ... who spearheaded the FDA statistical review -- began meeting regularly after ... FDA approved Aduhelm. Biogen's stock closed at $395.85 that ... Institute for Clinical and Economic Review, a nonprofit research and advisory ...
Asymmetric
Published on 2022-01-05 in the Biotech forum
This discussion is in English.
How Biogen Fumbled Aduhelm, Its Once-Promising Alzheimer's Drug
... the price. The company's stock is trading at about half its 2021 ... the agency conducted a thorough review of Aduhelm's data and ... saw Dr. Dunn as an ally who had been supportive of ... who spearheaded the FDA statistical review -- began meeting regularly after ... FDA approved Aduhelm. Biogen's stock closed at $395.85 that ... Institute for Clinical and Economic Review, a nonprofit research and advisory ...
Asymmetric
Published on 2022-01-05 in the Biotech forum
This discussion is in English.